Publicaciones en colaboración con investigadores/as de University Hospital of Lausanne (9)

2024

  1. Influence of Pathophysiologic Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes

    Circulation, Vol. 150, Núm. 8, pp. 586-597

2023

  1. Impact of Post-PCI FFR Stratified by Coronary Artery

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 19, pp. 2396-2408

  2. Rationale and design of the pullback pressure gradient (PPG) global registry

    American Heart Journal, Vol. 265, pp. 170-179

2022

  1. Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years

    Cardiovascular Revascularization Medicine, Vol. 38, pp. 106-110

2019

  1. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment

    Journal of the American College of Cardiology, Vol. 73, Núm. 4, pp. 444-453

  2. Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses: A Multicenter Study Using Intracoronary Pressure and Flow

    Circulation. Cardiovascular interventions, Vol. 12, Núm. 12, pp. e008263

  3. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 5, pp. 392-398

2016

  1. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

    The Lancet, Vol. 387, Núm. 10013, pp. 31-39

  2. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

    European Heart Journal, Vol. 37, Núm. 35, pp. 2701-2709